349 related articles for article (PubMed ID: 34176946)
21. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O; Hasanov E; Wilson NR; Araujo J; Wang J; Campbell MT; Goswami S; Shah AY; Gao J; Msaouel P; Tannir NM
Int J Cancer; 2021 Jul; 149(2):387-393. PubMed ID: 33739450
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Tanaka T; Hatakeyama S; Numakura K; Kido K; Noro D; Oikawa M; Hosogoe S; Tokui N; Yamamoto H; Narita S; Ito H; Yoneyama T; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Urol; 2020 Dec; 27(12):1095-1100. PubMed ID: 32893401
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
[TBL] [Abstract][Full Text] [Related]
25. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
27. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
[TBL] [Abstract][Full Text] [Related]
28. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
29. Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors.
Kato R; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
Int Immunopharmacol; 2022 Dec; 113(Pt B):109443. PubMed ID: 36403521
[TBL] [Abstract][Full Text] [Related]
30. Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab.
Blas L; Shiota M; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
Clin Genitourin Cancer; 2024 Feb; 22(1):e122-e127.e1. PubMed ID: 37813699
[TBL] [Abstract][Full Text] [Related]
31. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
[TBL] [Abstract][Full Text] [Related]
33. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
[TBL] [Abstract][Full Text] [Related]
34. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
35. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
[TBL] [Abstract][Full Text] [Related]
36. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
38. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.
Xing P; Zhang F; Wang G; Xu Y; Li C; Wang S; Guo Y; Cai S; Wang Y; Li J
J Immunother Cancer; 2019 Dec; 7(1):341. PubMed ID: 31801636
[TBL] [Abstract][Full Text] [Related]
39. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
Takada R; Fujiwara M; Maki M; Nomura N; Kono S; Fujita A; Masumoto H; Takahashi Y; Hasegawa Y; Tamura K
J Pharm Health Care Sci; 2024 May; 10(1):26. PubMed ID: 38822426
[TBL] [Abstract][Full Text] [Related]
40. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
